Basel, August 25, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko® (natalizumab-sztn), developed by Polpharma Biologics….Original Article
FDA Approves Tyruko (natalizumab-sztn), a Biosimilar to Tysabri
